High hurdle of clinical trials to demonstrate efficacy of anticataractogenic drugs.
Recently, the rapid progression of cataract surgical technique has led cataract patients in industrialized countries to ignore the possibilities of drug therapy. Globally, however, it will be impossible in the near future to treat cataract by surgery alone, mainly due to medicoeconomic reasons. Preventative measures must be sought. As one of the these measures, the development of anticataractogenic drugs has reemerged as a focus in the lens research field. Although clinical trials of newly developed drugs are absolutely necessary before they enter the market, they have been considered to be a rather easy task. However, in order to gain accurate and reproducible data from trials, the trial program must be carefully prepared. The numbers of participants to the trial, the selection criteria of the subjects, the objective judgment of cataractous changes, follow-up period, a high technical level for cataract documentation and image analysis are proposed. Although there still remain some difficulties concerning the methods for objective judgment, a scientifically acceptable examination must be conducted.
Sasaki
K
K
Department of Ophthalmology, Kanazawa Medical University, Uchinada, Japan. sasaki-k@kanazawa-med.ac.jp
Hockwin
O
O
Sakamoto
Y
Y
Sasaki
H
H
Kojima
M
M
D000818:Animals; D002386:Cataract / Q000145:classification / Q000188:drug therapy* / Q000473:pathology; D003941:Diagnostic Techniques, Ophthalmological; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007091:Image Processing, Computer-Assisted; D010781:Photography / Q000379:methods; D016032:Randomized Controlled Trials as Topic / Q000592:standards*; D012449:Safety